Understanding scleroderma-related PAH

Understanding scleroderma-related PAH

 
PAH Stops at nothing
Are you armed with information you need to ask your doctor about delaying PAH progression?
Sign up for more information
Scleroderma is a type of connective tissue disease (CTD). Some patients with scleroderma may also develop PAH.1-3
People with scleroderma have a higher risk for developing PAH. About 5% to 12% of patients with scleroderma develop PAH.1-4
When PAH arises as a complication of CTD such as scleroderma, it may progress rapidly, which is why timely diagnosis and treatment are important.5
The connection
between PAH and
scleroderma
The connection between
PAH and scleroderma
PAH may be the result of the same processes that cause scleroderma. In scleroderma, the blood vessels are injured or damaged. This causes a build-up of connective tissue and causes the blood vessels to narrow. These changes make it difficult for blood to flow. As a result, your heart must work harder to pump blood from the right side of your heart through the arteries of your lungs, which lowers the supply of oxygen to your body.1-3
Find out if there is an additional treatment angle you could try to help delay PAH progression6
Learn more
IMPORTANT SAFETY INFORMATION
EXPAND +
What is the most important information about UPTRAVI?
Who should not take UPTRAVI?
  • Do not take UPTRAVI if you take gemfibrozil because this medicine may affect how UPTRAVI works and cause side effects
What is UPTRAVI?

UPTRAVI® (selexipag) is a prescription medicine used to treat pulmonary arterial hypertension (PAH, WHO Group 1), which is high blood pressure in the arteries of your lungs.

UPTRAVI can help delay (slow down) the progression of your disease and lower your risk of being hospitalized for PAH.

It is not known if UPTRAVI is safe and effective in children.

What should I tell my doctor before taking UPTRAVI?

Tell your doctor if you:

  • Have liver problems
  • Have narrowing of the pulmonary veins (veins in your lungs). This is called pulmonary veno-occlusive disease (PVOD)
  • Are pregnant or plan to become pregnant. It is not known if UPTRAVI will harm your unborn baby
  • Are breastfeeding or plan to breastfeed. It is not known if UPTRAVI passes into your breast milk. You and your doctor should decide if you will take UPTRAVI or breastfeed. You should not do both
  • Have any other medical conditions
  • Are taking any other prescription or over-the-counter medicines, vitamins, or herbal supplements
What are the possible side effects of UPTRAVI?

The most common side effects are:

  • Headache
  • Diarrhea
  • Jaw pain
  • Nausea
  • Muscle pain
  • Vomiting
  • Pain in arms or legs
  • Temporary reddening of the skin (flushing)
  • Joint pain
  • Low red blood cell count
  • Less appetite than usual
  • Rash

Talk to your doctor if you have a side effect that bothers you or does not go away. These are not all the possible side effects of UPTRAVI. For more information, ask your doctor or pharmacist.

You may report side effects to FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.

Keep UPTRAVI and all other medicines away from children.

What other medicines might interact with UPTRAVI?
  • UPTRAVI and other medicines may affect each other, causing side effects. Tell your doctor about all the medicines you are taking. Do not start any new medicine until you check with your doctor
How should I take UPTRAVI?
  • Take UPTRAVI exactly as your doctor tells you to take it. Usually, your doctor will have you take UPTRAVI twice a day. Taking UPTRAVI with food may help you tolerate UPTRAVI better
  • Swallow UPTRAVI tablets whole. Do not split, crush, or chew tablets
  • Tell your doctor if you have any form of liver disease. Your doctor may need to change your dose of UPTRAVI
  • UPTRAVI is measured in micrograms (mcg). Tablets come in the following strengths: 200, 400, 600, 800, 1000, 1200, 1400, and 1600 mcg
What is UPTRAVI?

UPTRAVI® (selexipag) is a prescription medicine used to treat pulmonary arterial hypertension (PAH, WHO Group 1), which is high blood pressure in the arteries of your lungs.

UPTRAVI can help delay (slow down) the progression of your disease and lower your risk of being hospitalized for PAH.

It is not known if UPTRAVI is safe and effective in children.

Please see full Prescribing Information and Patient Product Information.

+
IMPORTANT SAFETY INFORMATION
What is the most important information about UPTRAVI?
+
What is UPTRAVI?

UPTRAVI® (selexipag) is a prescription medicine used to treat pulmonary arterial hypertension

IMPORTANT SAFETY INFORMATION
What is the most important information about UPTRAVI?
Who should not take UPTRAVI?
  • Do not take UPTRAVI if you take gemfibrozil because this medicine may affect how UPTRAVI works and cause side effects
What is UPTRAVI?

UPTRAVI® (selexipag) is a prescription medicine used to treat pulmonary arterial hypertension (PAH, WHO Group 1), which is high blood pressure in the arteries of your lungs.

UPTRAVI can help delay (slow down) the progression of your disease and lower your risk of being hospitalized for PAH.

It is not known if UPTRAVI is safe and effective in children.

What should I tell my doctor before taking UPTRAVI?

Tell your doctor if you:

  • Have liver problems
  • Have narrowing of the pulmonary veins (veins in your lungs). This is called pulmonary veno-occlusive disease (PVOD)
  • Are pregnant or plan to become pregnant. It is not known if UPTRAVI will harm your unborn baby
  • Are breastfeeding or plan to breastfeed. It is not known if UPTRAVI passes into your breast milk. You and your doctor should decide if you will take UPTRAVI or breastfeed. You should not do both
  • Have any other medical conditions
  • Are taking any other prescription or over-the-counter medicines, vitamins, or herbal supplements
What are the possible side effects of UPTRAVI?

The most common side effects are:

  • Headache
  • Diarrhea
  • Jaw pain
  • Nausea
  • Muscle pain
  • Vomiting
  • Pain in arms or legs
  • Temporary reddening of the skin (flushing)
  • Joint pain
  • Low red blood cell count
  • Less appetite than usual
  • Rash

Talk to your doctor if you have a side effect that bothers you or does not go away. These are not all the possible side effects of UPTRAVI. For more information, ask your doctor or pharmacist.

You may report side effects to FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.

Keep UPTRAVI and all other medicines away from children.

What other medicines might interact with UPTRAVI?
  • UPTRAVI and other medicines may affect each other, causing side effects. Tell your doctor about all the medicines you are taking. Do not start any new medicine until you check with your doctor
How should I take UPTRAVI?
  • Take UPTRAVI exactly as your doctor tells you to take it. Usually, your doctor will have you take UPTRAVI twice a day. Taking UPTRAVI with food may help you tolerate UPTRAVI better
  • Swallow UPTRAVI tablets whole. Do not split, crush, or chew tablets
  • Tell your doctor if you have any form of liver disease. Your doctor may need to change your dose of UPTRAVI
  • UPTRAVI is measured in micrograms (mcg). Tablets come in the following strengths: 200, 400, 600, 800, 1000, 1200, 1400, and 1600 mcg
What is UPTRAVI?

UPTRAVI® (selexipag) is a prescription medicine used to treat pulmonary arterial hypertension (PAH, WHO Group 1), which is high blood pressure in the arteries of your lungs.

UPTRAVI can help delay (slow down) the progression of your disease and lower your risk of being hospitalized for PAH.

It is not known if UPTRAVI is safe and effective in children.

Please see full Prescribing Information and Patient Product Information.

cp-113991v2

References: 1. Simonneau G, Gatzoulis MA, Adatia I, et al. Updated clinical classification of pulmonary hypertension. J Am Coll Cardiol. 2013;62(25)(suppl D):D34-D41. 2. Pulmonary Hypertension Association. Scleroderma and Pulmonary Hypertension. https://phassociation.org/patients/aboutph/diseases-and-conditions-associated-with-ph/scleroderma. Accessed November 27, 2017. 3. Scleroderma Foundation. Pulmonary Hypertension in Scleroderma. Danvers, MA: Scleroderma Foudation; 2017. 4. Galie N, Eur Heart J. European Heart Journal. 2016;37(67-119). 5. McLaughlin V, Humbert M, Coghlan G, Nash P, Steen V. Pulmonary arterial hypertension: the most devastating vascular complication of systemic sclerosis. Rheumatology (Oxford). 2009;48(Suppl 3):iii25-31. 6. McLaughlin VV, Archer SL, Badesch DB, et al. ACCF/AHA 2009 expert consensus document on pulmonary hypertension. Circulation. 2009;119(16):2250-2294.

You are now leaving Uptravi.com

Janssen offers this link to the third-party website as a courtesy to the Internet community and is not responsible for any content published on the third-party website you are about to enter. Janssen has not reviewed and does not endorse any information presented on the third-party website. Please see the Legal Notice for more information.

X
×